Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transepithelial CXL Riboflavin Dosing Study
NCT04905108Phase 3Recruiting
- Sponsor
- Cornea and Laser Eye Institute
- Start
- Jun 2021
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of riboflavin in keratoconus and corneal ectasia (2 arms), sponsored by Cornea and Laser Eye Institute. Primary endpoint: Maximum keratometry (Kmax) at 12 months. Started Jun 2021; status: recruiting.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT04905108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905108.